Precision BioSciences, Inc.

NasdaqCM DTIL

Precision BioSciences, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024: 5.20%

Precision BioSciences, Inc. Return on Assets (ROA) is 5.20% for the Trailing 12 Months (TTM) ending September 30, 2024, a 112.81% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Precision BioSciences, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2023 was -40.58%, a 10.25% change year over year.
Precision BioSciences, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2022 was -45.21%, a -209.51% change year over year.
Precision BioSciences, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2021 was -14.61%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: DTIL

Precision BioSciences, Inc.

CEO	Mr. Michael Amoroso
IPO Date	March 28, 2019
Location	United States
Headquarters	302 East Pettigrew Street
Employees	108
Sector	Healthcare
Industries Biotechnology

Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Key trends

Past 5 years